Touyun Biotech Group Limited (Touyun Biotech) filed its Monthly Return for September 2026, outlining a material increase in issued share capital.

Share Capital Dynamics • Authorised share capital remained unchanged at HKD 500.00 million, representing 12.50 billion ordinary shares with a par value of HKD 0.04 each. • Issued shares (excluding treasury shares) rose by 123.00 million during the month, moving from 2.81 billion to 2.93 billion. The company holds no treasury shares. • The additional shares were allotted on 7 September 2026 under a general mandate, priced at HKD 0.122 per share, implying gross proceeds of approximately HKD 15.01 million.

Public Float • Touyun Biotech confirmed compliance with the Main Board’s 25 % minimum public-float requirement as of 30 September 2026.

Equity-linked Securities • No options were exercised, and no warrants or convertible securities were outstanding. • Share options outstanding at month-end totalled 213.08 million across four schemes, including a new grant of 74.58 million options on 24 September 2026 at an exercise price of HKD 0.20 per share.

Treasury Activity • The company reported no share repurchases, cancellations or transfers of treasury shares during the period.

Regulatory Compliance • The board confirmed that all securities issuances complied with Hong Kong Stock Exchange listing rules and relevant legal requirements.

With the latest issuance, Touyun Biotech’s enlarged share base stands at 2.93 billion ordinary shares, positioning the company for future corporate initiatives while maintaining regulatory public-float thresholds.